Merck and Pfizer Provide Update on Avelumab in Platinum-Resist...
DARMSTADT, Germany and NEW YORK, November 19, 2018 /PRNewswire-AsiaNet/ -- Not intended for US, Canada and UK-based mediaMerck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxorubicin (PLD), a ty...
Read more https://view-release/?pr-id=76373